FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+CD25high T cells in multiple sclerosis

Clinical and Experimental Immunology

Volumn 170, Issue 2, 2012, Pages 149-155

  Sellebjerg, F ^a   Krakauer, M ^a   Khademi, M ^b   Olsson, T ^b   Sorensen P S ^a  

^a Rigshospitalet   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CTLA 4; Interferon treatment; Multiple sclerosis; Regulatory T cells

Indexed keywords

BETA1A INTERFERON; CBL PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 4; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; UBIQUITIN PROTEIN LIGASE E3;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CBLB GENE; CD4+ CD25+ T LYMPHOCYTE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; FOXP3 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; ITCH GENE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MALE; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TH2 CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; INTERFERON-BETA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MULTIPLE SCLEROSIS; PROTO-ONCOGENE PROTEINS C-CBL; REPRESSOR PROTEINS; RNA, MESSENGER; UBIQUITIN-PROTEIN LIGASES;

EID: 84867207124     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04654.x     Document Type: Article

References (48)

1. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65:239-248.
2. Bielekova B, Muraro PA, Golestaneh L etal. Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7. J Neuroimmunol 1999; 100:115-123.
3. Correale J, Gilmore W, McMillan M etal. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995; 154:2959-2968.
4. Zhang J, Markovic-Plese S, Lacet B etal. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179:973-984.
5. Olsson T, Zhi WW, Hojeberg B etal. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 1990; 86:981-985.
6. Hedegaard CJ, Krakauer M, Bendtzen K etal. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008; 125:161-169.
7. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008; 4:384-398.
8. Anderton SM, Liblau RS. Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol 2008; 21:248-254.
9. Baecher-Allan C, Brown JA, Freeman GJ etal. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-1253.
10. Liu W, Putnam AL, Xu-Yu Z etal. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006; 203:1701-1711.
11. Haas J, Hug A, Viehover A etal. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35:3343-3352.
12. Haas J, Fritzsching B, Trubswetter P etal. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 2007; 179:1322-1330.
13. Kumar M, Putzki N, Limmroth V etal. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006; 180:178-184.
14. Venken K, Hellings N, Hensen K etal. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83:1432-1446.
15. Venken K, Hellings N, Thewissen M etal. Compromised CD4+CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008; 123:79-89.
16. Viglietta V, Baecher-Allan C, Weiner HL etal. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:971-979.
17. Michel L, Berthelot L, Pettre S etal. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest 2008; 118:3411-3419.
18. Fletcher JM, Lonergan R, Costelloe L etal. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183:7602-7610.
19. Yagi H, Nomura T, Nakamura K etal. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004; 16:1643-1656.
20. Walker MR, Kasprowicz DJ, Gersuk VH etal. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J Clin Invest 2003; 112:1437-1443.
21. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8:277-284.
22. Bacchetta R, Passerini L, Gambineri E etal. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116:1713-1722.
23. Venuprasad K, Huang H, Harada Y etal. The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat Immunol 2008; 9:245-253.
24. Wohlfert EA, Gorelik L, Mittler R etal. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J Immunol 2006; 176:1316-1320.
25. Zhou WB, Wang R, Deng YN etal. Study of Cbl-b dynamics in peripheral blood lymphocytes isolated from patients with multiple sclerosis. Neurosci Lett 2008; 440:336-339.
26. de Andres C, Aristimuno C, de Las Heras V etal. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007; 182:204-211.
27. Venken K, Hellings N, Broekmans T etal. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol 2008; 180:6411-6420.
28. Sellebjerg F, Krakauer M, Limborg S etal. Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. PLoS ONE 2012; 7:e35927.
29. Krakauer M, Sorensen PS, Khademi M etal. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand J Immunol 2006; 64:155-163.
30. Krakauer M, Sorensen P, Khademi M etal. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008; 14:622-630.
31. Huan J, Culbertson N, Spencer L etal. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; 81:45-52.
32. Edstrom M, Mellergard J, Mjosberg J etal. Transcriptional characteristics of CD4+ T cells in multiple sclerosis: relative lack of suppressive populations in blood. Mult Scler 2011; 17:57-66.
33. Sakaguchi S, Miyara M, Costantino CM etal. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500.
34. Dieckmann D, Plottner H, Berchtold S etal. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193:1303-1310.
35. Jonuleit H, Schmitt E, Stassen M etal. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193:1285-1294.
36. Levings MK, Sangregorio R, Roncarolo MG. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193:1295-1302.
37. Ng WF, Duggan PJ, Ponchel F etal. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98:2736-2744.
38. Taams LS, Smith J, Rustin MH etal. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001; 31:1122-1131.
39. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 2003; 3:544-556.
40. Linsley PS, Bradshaw J, Greene J etal. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996; 4:535-543.
41. Kosmaczewska A, Bilinska M, Ciszak L etal. Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS). J Neuroimmunol 2007; 189:137-146.
42. Mena E, Rohowsky-Kochan C. Expression of costimulatory molecules on peripheral blood mononuclear cells in multiple sclerosis. Acta Neurol Scand 1999; 100:92-96.
43. Oliveira EM, Bar-Or A, Waliszewska AI etal. CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. J Autoimmun 2003; 20:71-81.
44. Gavin MA, Rasmussen JP, Fontenot JD etal. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445:771-775.
45. Zheng Y, Josefowicz SZ, Kas A etal. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445:936-940.
46. Sellebjerg F, Datta P, Larsen J etal. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 2008; 14:615-621.
47. Bulwin GC, Heinemann T, Bugge V etal. TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression. J Immunol 2006; 177:6833-6841.
48. Utku N, Boerner A, Tomschegg A etal. TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response. J Immunol 2004; 173:2342-2352.